A new study published in Physiology & Behavior uncovers significant sensory implications of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications commonly prescribed for weight loss and ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...